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Tokyo, JapanElucidation of acute kidney diseases and disorders (AKD),
including acute kidney injury (AKI), is important to prevent
their progression to chronic kidney disease. Current animal
AKI models are often too severe for use in evaluating
human AKI. Therefore, new animal models of mild kidney
injury are needed. Here a new clinically relevant animal
model using multiple low doses of cisplatin (CP) was used
to evaluate AKD. When 10 mg/kg CP was administered
intraperitoneally once weekly for three times to L-type fatty
acid-binding protein (L-FABP) transgenic mice, moderate
renal interstitial ﬁbrosis and tubule dilatation occurred,
accompanied by brush-border loss. Urinary L-FABP, a
promising biomarker of AKI, changed more drastically than
blood urea nitrogen or creatinine. Preventing ﬁbrosis in
organs was also studied. Oral administration of a recently
reported selective semicarbazide-sensitive amine oxidase
inhibitor, PXS-4728A, for 1 week attenuated kidney injury
and interstitial ﬁbrosis compared with vehicle. Inhibition of
renal lipid accumulation in semicarbazide-sensitive amine
oxidase inhibitor-treated mice, together with reduced
oxidative stress and L-FABP suppression in proximal
tubules, suggested an antiﬁbrotic effect of semicarbazide-
sensitive amine oxidase inhibition in this CP-AKD model, a
representative onco-nephrology. Thus, semicarbazide-
sensitive amine oxidase inhibitors may be promising
candidates for the prevention of chronic kidney disease in
patients using CP to treat malignancy.
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374A cute kidney injury (AKI) is a well-known candidatecause of chronic kidney disease (CKD).1 AKI is oneof the number of acute kidney diseases and disorders
(AKDs), which is a recently deﬁned concept to provide an
integrated clinical approach to patients with kidney abnor-
malities of function and structure.2 In AKD patients, each
AKI episode is associated with a cumulative risk of developing
CKD.3 Furthermore, even if patients ‘recover’ their renal
function after AKI, an increased risk of CKD progression
remains.4 To halt progression to end-stage renal disease, aside
from risk assessment and recognition,5,6 it is important to
investigate novel therapeutic targets associated with CKD pro-
gression after AKD. The great contribution of several current
animal models that mimic human AKI such as acute tubular
necrosis (ATN) after renal ischemia–reperfusion injury
cannot be overstated, but the models and procedures are
unfortunately often too severe and entail high mortality.7–9
Therefore, new, more AKD-relevant animal models of mild
kidney injury should be explored.
Kidney damage in the setting of AKI can induce a pro-
inﬂammatory tubular cell response with cytokine produc-
tion, leakage of albumin, complement proteins, and hypoxia.
Tubular epithelial cells can also be the main targets of renal
injury caused by immunologic, infectious, ischemic, and toxic
agents. Tubular cell activation causes interstitial leukocyte
recruitment. It can also trigger further maladaptive responses.
In fact, tubular cells can secrete pro-ﬁbrotic factors such as
unopposed transforming growth factor-b1 (TGF-b), which
can stimulate ﬁbroblast accumulation and interstitial collagen
deposition.10–12 Interstitial ﬁbrosis that impairs oxygen
diffusion is consistently associated with CKD as a ﬁnal
common pathway. Moreover, it is associated with activation
of myoﬁbroblasts and inﬂammatory cells, which have key
roles in the progression of tubular degeneration.13,14
Although macrophage and T-cell subsets, as well as certain
cytokines and immunoreactants, are associated with either
injury or repair, chronic dysregulation of these factors and
their net interactions are likely to determine the extent of
ﬁbrotic responses and kidney function impairment.15,16
In patients with malignancy, AKD is an important
complication, particularly because the life expectancy ofKidney International (2016) 89, 374–385
D Katagiri et al.: SSAO/VAP-1 inhibitor for CP-AKD bas i c re sea r chpatients with cancer has increased during the last decade.17
Cisplatin (CP), a platinum compound that is used as an
effective chemotherapeutic agent for many carcinomas, sar-
comas, and lymphomas, has acute dose-dependent nephro-
toxicity, which often limits its administration.18 Prevention of
kidney injury is currently the focus of care for patients
receiving CP because of the lack of effective therapies to
reverse tubular dysfunction when maladaptive injury occurs.19
Clinically, CP-induced AKI (CP-AKI) is often observed after
10 days of CP administration in patients, in whom it presents
as a decreased glomerular ﬁltration rate and an increased
serum creatinine (Cre).20 AKI induced by a high dose of CP is
a well-studied model of nephrotoxicity in rodents. In mouse
models, CP-AKI occurs dose dependently. A large increase in
blood urea nitrogen (BUN) is apparent 48 h after CP injec-
tion.21 Exposure of tubular epithelial cells to CP activates
complex signaling pathways that engender cell injury and
death. Although the apoptotic pathway has been regarded as
the main target for the management of CP-AKI among these
pathways, an antioxidative strategy might also be effective.20 A
model of chronic kidney injury induced by a single CP in-
jection presents with glomerular sclerosis, cyst formations,
and interstitial ﬁbrosis.22,23 In this study, we administered
multiple lower CP doses in mice and evaluated the potential
of this approach as a clinically relevant AKD model in vivo.
Because urinary L-type fatty acid-binding protein (L-FABP)
shows promise as an AKI biomarker and because it has also
been reported to assist in predicting CKD,24–28 we evaluated
AKD in L-FABP transgenic (Tg) mice.
Furthermore, we tested the potential of a selective
semicarbazide-sensitive amine oxidase (SSAO) inhibitor
(SSAOi) to ameliorate kidney injury in this model. SSAO (also
known as amine oxidase, copper-containing 3 and vascular
adhesion protein-1 [VAP-1]) is a circulating, type-1
membrane-bound protein that has a distal adhesion domain
and a catalytic amine oxidase site proximal to the membrane.29
Expressed predominantly in the endothelium and leukocytes, it
has a dual role in mediating inﬂammation and reactive
oxygen species production.30–32 The expression of SSAO/VAP-1
increases in response to inﬂammatory stimuli such as heart
failure, diabetes mellitus, and CKD and to non-inﬂammatory
conditions including cerebral infarction, pulmonary ﬁbrosis,
and cirrhosis.33–37 Recently, antiﬁbrotic and antioxidative
effects of SSAOi have been reported.38 This study is the ﬁrst
to assess the role of SSAOi in a model of AKD with multiple
CP administrations using L-FABP Tg mice and the ﬁrst to
demonstrate its applicability to onco-nephrology.
RESULTS
Multiple administrations of CP-induced AKD in L-FABP Tg
mice
Male L-FABP Tg mice heterozygous for human L-FABP
(C57BL/6 background) were administered three 10 mg/kg CP
doses (at 0, 1, 3 weeks (W)) or the same dose of saline for
4 W. The mice were killed at 4 W after the ﬁrst CP injection.
Their kidneys were collected for analyses. Remarkably,Kidney International (2016) 89, 374–385increased BUN and Cre were observed at 4W (Figure 1a and b).
Urinary L-FABP, a promising early AKI biomarker,39,40
increased about 10-fold 1 W after every CP injection.
Although no further elevation of L-FABP was observed at 3 W,
following the omission of CP at 2 W, L-FABP did not revert
to baseline levels (Figure 1c). Pathological analysis at 4 W
revealed tubule dilatation accompanied by brush-border loss
and moderate renal interstitial ﬁbrosis (Figure 1d and e).
To assess the cumulative CP-induced toxicity for this model,
some mice (n ¼ 6) were killed at 3 W. Moderate renal inter-
stitial ﬁbrosis was seen at 3 W, which deteriorated at 4 W
(Figure 1e). Although lower CP doses (3 mg/kg and 5 mg/kg; 0,
1, and 3 W) hardly affected BUN or Cre, 10 mg/kg CP
signiﬁcantly elevates BUN and Cre (Supplementary Figure S1A
and B online), and the ﬁbrotic change with a dose-dependent
tendency was conﬁrmed at 4W by Masson’s trichrome (MT)
staining (Supplementary Figure S1C and D online). The body
weight and white blood cell count of Tg mice were reduced
signiﬁcantly at 4 Wafter the ﬁrst CP dose. No notable difference
was visible in hemoglobin, red blood cell, or platelet counts
(Supplementary Figure S2 online). No signiﬁcant difference
was visible in BUN or Cre increase between wild-type and
L-FABP Tg mice (Supplementary Figure S3A and B online). We
regarded these changes to be a result of sub-acute renal damage
induced by multiple CP injections, indicating this protocol as a
feasible CP-AKD under an onco-nephrology setting. We
therefore tried to assess the protective effects of SSAOi in this
model.
Effects of SSAOi on renal function and histo-pathological
changes in the CP-AKD model
In the preliminary experiment, treatment with PXS-4728A, a
selective SSAOi (2 mg/kg per day), alone for 7 days did not
affect renal function or pathology (Supplementary Figure S3C
and D online). Therefore, L-FABP Tg mice received oral doses
of PXS-4728A (2 mg/kg per day) or vehicle in a volume of
10 ml/kg starting 3 W after the ﬁrst CP administration
(Supplementary Figure S4 online). The increases in BUN,
Cre, and urinary L-FABP at 4 W were attenuated signiﬁcantly
by SSAOi treatment (Figure 2a–c). A ﬂuorometric assay using
kidney homogenate samples at 4 W revealed that the SSAO
activity in CPþvehicle mice was signiﬁcantly increased, but
that it was suppressed by SSAOi treatment (Figure 2d). Other
novel urinary AKI biomarkers such as neutrophil gelatinase–
associated lipocalin and KIM-1 (kidney injury molecule-1)
were conﬁrmed to have similar movement to that of
L-FABP in this model (Supplementary Figure S5A and B
online). Microalbuminuria occurred in this multiple CP
treatment model, but it was ameliorated with SSAOi treat-
ment (Supplementary Figure S5C online).
Pathological changes, gaugeable by the ATN score, found at
4 W, including tubule dilatation and brush-border losses, were
attenuated by SSAOi treatment (Figure 3a and b). Oxidative
stress was evaluated by immunohistochemical staining for
4-hydroxy-hexenal (4-HHE) and 8-hydroxydeoxyguanosine
(8-OHdG). Reportedly, these oxidative-stress markers increase375
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Figure 1 | Response to multiple CP treatments in the mouse CP–induced tubulointerstitial injury model. (a–c) Animals were administered
10 mg/kg CP three times over 4 W (0, 1, and 3 W). After exposure to CP, levels of BUN, Cre, and urinary L-FABP were signiﬁcantly higher at
4 W (n ¼ 7–8). L-FABP levels at 3 W were decreased according to the lack of CP injection at 2 W. (d) Exposure to CP caused brush-border loss at
4 W after three CP injections (bar ¼ 50 mm). (e) To assess the cumulative CP-induced toxicity for this model, some mice (n ¼ 6) were killed
at 3 W after ﬁrst CP injection. Moderate renal interstitial ﬁbrosis was already seen at 3 W after 2 CP injections, which signiﬁcantly deteriorated
at 4 W after the third CP injection (bar ¼ 50 mm). *P < 0.05. Data are expressed as mean values  SEM. BUN, blood urea nitrogen; CP, cisplatin;
Cre, creatinine; L-FABP, L-type fatty acid-binding protein; MT, Masson trichrome; PAS, periodic acid-Schiff; W, weeks.
bas i c re sea r ch D Katagiri et al.: SSAO/VAP-1 inhibitor for CP-AKDin renal ischemia–reperfusion or CP-AKI models.41 In this
study, accumulation of 4-HHE and 8-OHdG was detected in
renal tubular epithelial cells in CP-injected animals. SSAOi
treatment reduced 4-HHE-positive and 8-OHdG-positive areas
remarkably, as indicated by immunohistochemical analyses
(Figure 3a). Quantitative analysis of 4-HHE-positive and
8-OHdG-positive areas conﬁrmed the reduction in oxidative
stress by SSAOi treatment (Figure 3c). To assess tubular
superoxide levels, dihydroethidium (DHE) histochemical376analysis was performed as described previously.42 DHE signal
levels, which increased with multiple CP injections, were sup-
pressed with SSAOi treatment (Figure 3a and d).
Deposition of pathological ﬁbrillar matrix, with high
ﬁbrillar collagens I and III, in the potential space between
tubules and peritubular capillaries is characteristic of CKD.43
We evaluated the antiﬁbrotic effect of SSAOi treatment using
MT, collagen IV, and Sirius red stainings (Figure 4a and b).
Notable deposition of collagen I (yellow) and III (green) wasKidney International (2016) 89, 374–385
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Figure 2 | SSAOi ameliorated kidney injury and kidney SSAO activity. L-FABP Tg mice were orally administered 2 mg/kg per day PXS-4728A
(selective SSAOi) or vehicle in a volume of 10 ml/kg starting 3 W after the ﬁrst CP administration (see Supplementary Figure S4 online). Double-
headed arrow indicates the duration of intervention of saline (vehicle) or SSAOi treatment. (a, b, and c) Time courses of BUN and Cre. The
increase in BUN and Cre at 4 W was attenuated signiﬁcantly by SSAOi treatment (n ¼ 7–8). (c) SSAOi treatment suppressed the urinary L-FABP
elevation at 4 W (n ¼ 7–8). (d) SSAO activity in whole-kidney homogenates at 4 W (n ¼ 5–6; expressed as ratio to vehicle) was determined by
ﬂuorometry, indicating a signiﬁcant suppression of SSAO activity in SSAOi-treated mice. *P < 0.05 versus vehicle, #P < 0.05 versus CPþvehicle
group at 4 W. Data are expressed as mean values  SEM. BUN, blood urea nitrogen; CP, cisplatin; Cre, creatinine; L-FABP, L-type fatty acid-
binding protein; SSAOi, semicarbazide-sensitive amine oxidase inhibitor; Tg, transgenic; W, weeks.
D Katagiri et al.: SSAO/VAP-1 inhibitor for CP-AKD bas i c re sea r chfound in CPþvehicle mice and was alleviated signiﬁcantly in
CPþSSAOi mice (Figure 4a and c). These ﬁndings suggest
that multiple CP injections led to sub-acute renal ﬁbrosis,
which was suppressed by SSAOi. F4/80-positive inﬂammatory
cell (macrophage) inﬁltration in the interstitium was
increased by multiple CP administrations and was reduced by
SSAOi treatment (Figure 4a and d).
Effects of SSAOi on TGF-b, vascular endothelial growth factor,
a-smooth muscle actin, monocyte chemoattractant protein-1,
tumor necrosis factor-alpha, and interleukin-6 expression in
the kidney of the CP-AKD model
Reportedly, CP has a causal inﬂuence on renal ﬁbrosis via
TGF-b upregulation. Ramesh et al.44 reported previously that aKidney International (2016) 89, 374–385high CP dose (20 mg/kg) in mice led to an increase in TGF-b.
Using real-time reverse transcription polymerase chain reac-
tion, we assessed a-smooth muscle actin (a-SMA), a marker of
active myoﬁbroblasts in kidney disease,43,45 and vascular
endothelial growth factor (VEGF), which has a role in vascular
stability, but which leads to vascular leakage by destruction of
the vascular barrier at high levels.46 In our study, the expres-
sions of TGF-b, a-SMA, VEGF, and monocyte chemo-
attractant protein-1 in the kidney were increased signiﬁcantly
by multiple CP treatments and were attenuated by SSAOi
treatment (Figure 5a–d). In addition, the expressions of tumor
necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6) in the
kidney were increased signiﬁcantly by CP administration,
which was reduced by SSAOi treatment (Figure 5e and f).377
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Figure 3 | Morphological changes and oxidative stress induced by multiple CP administrations. (a) Formalin-ﬁxed sections were stained
with PAS and 4-HHE and 8-OHdG antibodies (bar ¼ 50 mm). Loss of brush-border and tubular degeneration were attenuated by SSAOi
treatment. Multiple CP administration caused severe accumulation of 4-HHE and 8-OHdG in damaged tubules, although this accumulation was
reduced remarkably by SSAOi treatment. DHE histochemistry was performed using frozen sections to examine tubular superoxide levels. Arrows
indicate DHE-positive interstitial (bar ¼ 50 mm). (b) Semiquantitative assessment of histological damage showed a signiﬁcant beneﬁcial effect of
SSAOi treatment in CP-AKI (n ¼ 5–6). (c) 4-HHE-positive and 8-OHdG-positive areas per  400 visual ﬁeld were increased at 4 W but were
reduced signiﬁcantly by SSAOi treatment (n ¼ 5–6). (d) DHE intensity ratio of CP-AKD kidney was increased signiﬁcantly, which was ameliorated
with SSAOi treatment (n ¼ 5–6; intensity ratio to the vehicle). Data are expressed as mean values  SEM. *P < 0.05 versus vehicle, #P < 0.05
versus CPþvehicle group. 4-HHE, 4-hydroxy-hexenal; 8-OHdG, 8-hydroxydeoxyguanosine; ATN, acute tubular necrosis; CP, cisplatin; DHE,
dihydroethidium; PAS, periodic acid-Schiff; SSAOi, semicarbazide-sensitive amine oxidase inhibitor.
bas i c re sea r ch D Katagiri et al.: SSAO/VAP-1 inhibitor for CP-AKDTubular accumulation of lipids and expression of L-FABP in
multiple CP dose–induced AKD
We previously reported CP-induced disorder of lipid meta-
bolism in the mouse kidney.47 In this study, Oil Red O
staining of kidney sections at 4 W revealed numerous cyto-
plasmic lipid droplets in outer medullary proximal tubules
after multiple CP treatment; this lipid accumulation was
attenuated by SSAOi (Figure 6a and b). Multiple CP admin-
istrations showed L-FABP-positive staining primarily in the
cytoplasm of the proximal tubular cells. Decreased L-FABP
expression in SSAOi-treated kidneys was conﬁrmed by results
of immunohistochemical analysis and of quantitative PCR
analysis (Figure 6c and d).378DISCUSSION
For this study, we tried to mimic clinical AKD by referring to
previous reports indicating that three doses of diphtheria toxin
at weekly intervals in mice exacerbated maladaptive injury,
with increased myoﬁbroblasts and tubulointerstitial ﬁbrosis.
In the same report, diphtheria toxin dose–dependent elevation
of KIM-1 was also conﬁrmed.48 Regarding this relation
between CP dosage and ﬁndings in this study, we referred to
the previous report showing that a one-time 12 mg/kg CP dose
induced mild renal damage and enabled survival beyond
4 days.49 Nishikawa et al.50 reported that daily 5 mg/kg CP for
3 consecutive days in cancer-bearing mice led to BUN elevation
of about 80 mg/dl, 96 h after the third treatment. RegardingKidney International (2016) 89, 374–385
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Figure 4 | Effect of SSAOi treatment on pro-ﬁbrotic changes after multiple CP administrations. (a) Antiﬁbrotic effects of SSAOi were
evaluated using MT, collagen IV, and Sirius red staining. Effects of SSAOi against accumulation of macrophages after multiple CP injections were
assessed using F4/80 staining (bar ¼ 50 mm). Notable deposition of collagen I (yellow) and III (green) was found in CP-AKD mouse kidneys and
was alleviated signiﬁcantly with SSAOi treatment, as conﬁrmed by Sirius red staining and polarizing microscopy. (b–d) MT-, collagen IV–,
collagen type I–, and III-positive areas and F4/80-positive cells per 400 visual ﬁeld were increased at 4 W after CP initiation but were reduced
signiﬁcantly by SSAOi treatment (n ¼ 5–6). Data are expressed as mean values  SEM. *P < 0.05 versus CPþvehicle group. CP, cisplatin; MT,
Masson trichrome; SSAOi, semicarbazide-sensitive amine oxidase inhibitor; W, weeks.
D Katagiri et al.: SSAO/VAP-1 inhibitor for CP-AKD bas i c re sea r chmultiple and chronic administrations, it had been reported
that repeated injections of 2 mg/kg CP once weekly for 10W in
rats led to ﬁbrosis around the dilated renal proximal tubules.51
For this study, multiple administrations of 10 mg/kg CP (three
times in 4 W) were used to evaluate whether the model is
illustrative of AKD because of CP nephrotoxicity. Initially,
L-FABP detects every minor injury to proximal tubules and
returns to the baseline. However, the baseline becomes higher
with repetition. Actually, the L-FABP levels at 3 W decreased
according to the skip of CP injection at 2 W, which did not
return to baseline, suggesting a causal relation of each mild
AKI and the development of CKD as a mild but a cumulative
CP toxicity, which corresponds to the illness trajectory of
AKD. Other emerging AKI biomarkers such as neutrophil
gelatinase–associated lipocalin and KIM-1 are also regarded as
useful. The high-level transition of L-FABP is expected to
correspond with its reactivity to the chronic hypoxic stressKidney International (2016) 89, 374–385with multiple CP injections20 because the promoter region of
FABP gene has a hypoxia-responsive element.52 Appearance of
microalbuminuria that is apparent to the end of the experi-
ment suggests the preamble from AKD to CKD transition in
this model.
The progression of CKDwith interstitial ﬁbrosis subsequent
to acute proximal tubular injury has been studied.14 If injury to
the proximal tubules is severe or repeated beyond the adaptive
repair potential of the kidney, or occurring in the context of
abnormal conditions, then epithelial cells become arrested in
the G2/M phase of the cell cycle, and production of pro-ﬁbrotic
factors, including TGF-b, is enhanced.53 Injured epithelial cells
produce TGF-b, which leads to the increased production of
a-SMA, F-actin, and collagen I byﬁbroblasts.54,55 VEGFhas been
reported to stimulate the proliferation of peritubular capillaries
and interstitial ﬁbroblasts, with subsequent matrix deposition
without damaging the tubules in VEGF-overexpressing mice.56379
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Figure 5 | Effects of SSAOi on TGF-b, VEGF, a-SMA, MCP-1, TNF-a, and IL-6 expression in the kidneys of CP-AKD mice. The mRNA
expressions of (a–f) TGF-b, VEGF, a-SMA, MCP-1, TNF-a, and IL-6 in the kidney at 4 W were increased signiﬁcantly by multiple CP treatments and
were suppressed by SSAOi treatment (n ¼ 5–6). 18 S rRNA in each experiment was used to normalize the relative expression of the genes of
interest to 18s rRNA. Data are expressed as mean values  SEM. *P < 0.05 versus vehicle, #P < 0.05 versus CPþvehicle. a-SMA, alpha smooth
muscle actin; AKD, acute kidney diseases and disorders; CP, cisplatin; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; SSAOi,
semicarbazide-sensitive amine oxidase inhibitor; TGF-b, transforming growth factor-b1; TNF-a, tumor necrosis factor-alpha; VEGF, vascular
endothelial growth factor.
bas i c re sea r ch D Katagiri et al.: SSAO/VAP-1 inhibitor for CP-AKDConsidering that TGF-b increases but that VEGF decreases
in the early phase of ischemia–reperfusion injury-AKI, and
considering the fact that both TGF-b and VEGF increased
in our study, a more delayed phase of AKI induced by multiple
CP treatments was observed.57
In the normal kidney, L-FABP is expressed predominantly
in proximal epithelial tubular cells. Because L-FABP can act as a
surrogate molecule that ameliorates lipid peroxidative stress in
proximal tubules, upregulation of L-FABP might decrease
kidney damage in several AKI settings.39,52 Urinary L-FABP has
also been reported to assist in predicting the progression of
CKD staging.27,28 A signiﬁcant upregulation of urinary L-FABP
in the early phase (2 W) might provide a more incisive indi-
cation of kidney injury than BUN, the traditional kidney injury
biomarker, which presents an opportunity for earlier inter-
vention. This report is the ﬁrst of the performance of urinary
L-FABP in the setting of the AKD mice model. We earlier
reported that urinary L-FABP reﬂected renal ﬁbrosis in
adenine-induced tubulointerstitial injury in mice, although
albumin or N-acetyl-b-D-glucosaminidase did not.58 Repeated
hypoxia induced by each CP dose in this study would decrease
peritubular capillary blood ﬂow, leading to tubulointerstitial380damage and upregulation of L-FABP.59 Given that 4-HHE is a
highly toxic aldehyde that is generated during lipid peroxida-
tion,47 prevention of lipid accumulation and L-FABP upregu-
lation in the proximal tubules in the present study appears to be
associated with the amelioration of oxidative stress by SSAOi
treatment rather than the protective function of L-FABP per se
in this CP-induced kidney injury model.
Amine oxidases are a family of enzymes that catalyze the
oxidation of widely various endogenous amines such as hista-
mine or dopamine. Two classes of amine oxidases exist: ﬂavin
dependent, such as monoamine oxidase A and B, and copper
dependent, such as lysyl oxidase and lysine demethylase. SSAO,
also known as VAP-1, is a copper-dependent amine oxidase.60
SSAO/VAP-1, which is predominantly located in the endothe-
lium and which mediates leukocyte migration, is highly active
in the endothelial cells of highly vascularized tissues, including
kidney, liver, gonads, and fat tissues.37,61 The pathological role
of SSAO in ﬁbrotic disease has been previously reported in
murine models of liver injury62 and arterial remodeling.63 The
soluble form of SSAO/VAP-1 is a biomarker of disease pro-
gression in patients with liver and kidney ﬁbrosis,64,65 cancer,66
cardiovascular disease,66,67 and metabolic disorders.68,69 SSAOKidney International (2016) 89, 374–385
CP + vehicle CP + SSAOi
CP + vehicle CP + SSAOi
O
il r
ed
L-
FA
BP
CP +
vehicle
CP + 
SSAOi
O
il r
ed
 p
os
itiv
e
 a
re
a
 (%
)
12.0
10.0
8.0
6.0
4.0
2.0
0.0
*
CP +
vehicle
CP + 
SSAOi
3.0
2.5
2.0
1.5
1.0
0.5
0.0
*
L-
FA
BP
/1
8s
 rR
NA
a
c
b
d
Figure 6 | Lipid accumulation in CP-AKD was attenuated by SSAO inhibition. (a and b) Signiﬁcant lipid accumulation in the cytoplasmic
region of the outer medullary proximal tubules in the multiple CP-treated mouse kidney was attenuated with SSAOi treatment (n ¼ 5–6;
bar ¼ 500 mm in the upper row and 50 mm in the lower row). (c) Immunohistochemical staining for L-FABP. Cytoplasmic staining of L-FABP in
proximal tubules was enhanced in CP-AKD (n ¼ 5–6, bar ¼ 200 mm in the upper row and 50 mm in the lower row). (d) Decreased expression of
L-FABP mRNA in the SSAOi-treated kidney conﬁrmed with real-time RT-PCR analysis (n ¼ 5–6). Data are expressed as mean values  SEM.
*P < 0.05 versus CPþvehicle group. AKD, acute kidney diseases and disorders; CP, cisplatin; L-FABP, L-type fatty acid-binding protein; SSAOi,
semicarbazide-sensitive amine oxidase inhibitor. RT-PCR, reverse transcription polymerase chain reaction.
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generation of aldehyde, ammonia, and hydrogen peroxide.70
Endogenous substrates of SSAO include methylamine and
aminoacetone, the products of which (formaldehyde and
methylglyoxal) are notably reactive and cytotoxic, leading to
cross-linking of protein and oxidative stress.71–73Methylamine,
which in itself is nontoxic to endothelial cells, becomes highly
toxic in the presence of SSAO.71 In CKD patients, blood
methylamine levels arew20-fold higher than those in people
with a normal kidney function because the urinary excretion of
methylamine is reduced markedly.74,75
Wong et al.38 reported that PXS-4728A reduced oxidative
stress and collagen accumulation, together with suppressing
TGF-b, in an obstructive nephropathy model. PXS-4728A,
which is a highly selective mechanism-based SSAOi when
proﬁled against related amine oxidases, is superior to previ-
ously reported inhibitors such as PXS-4681A.76 Single oralKidney International (2016) 89, 374–385dosing of 2 mg/kg PXS-4728A, as used in our model, provides
>80% inhibition of SSAO in various tissues. Reportedly,
enzyme recovery occurs with a half-life of 2–3 days.38,77 Re-
sults of the present study conﬁrmed that PXS-4728A sufﬁ-
ciently suppressed SSAO/VAP-1 activity in the kidney
following daily 2 mg/kg treatment. We infer that the changes
observed at 4 W are mainly attributable to cumulative CP
toxicity rather than acute effects observed at 3 W. Surpris-
ingly, the MT-positive area at 3 W was almost the same degree
as that seen at 4 W in the CPþSSAOi treatment group. These
ﬁndings demonstrate the efﬁcacy of SSAOi on prevention of
the additional toxicity of CP in this model.
In patients with malignancy who receive chemotherapy
including CP, oxidative stress cannot be ignored.20,78 Reactive
oxygen species generated by CP can increase renal lipid
peroxidation.79 Reactive oxygen species can react with the
polyunsaturated fatty acids of lipid membrane and induce lipid381
bas i c re sea r ch D Katagiri et al.: SSAO/VAP-1 inhibitor for CP-AKDperoxidation. 4-HHE, which was increased in this study, is an
end product of lipid peroxidation and a second messenger of
oxidative stress similarly to 4-HNE.78 Increased SSAO
expression is regarded as contributing to oxidative stress,
generating advanced glycation end products.80 Inhibition of
lipid accumulation in SSAOi-treated mouse kidney in this
study was caused by a reduction in oxidative stress and a lesser
induction of L-FABP, a lipid chaperon, in proximal tubules. In
CP-AKI or diabetic kidney disease, an accumulation of lipids
seen as Oil Red O staining in our study in tubules has been
proposed as the hallmark of CKD progression.81,82 The
enzymes and regulators of FAO (fatty acid oxidation) have
received renewed attention for reduction in kidneys from
human subjects with CKD and in mouse models of kidney
ﬁbrosis with gene proﬁling.83 Although we did not measure
FAO, our results are consistent with the possibility that SSAOi
increased the rate of FAO in this model of CP-AKD. Currently,
clinical trials aimed at alleviating the pro-ﬁbrosis environment
and at reducing epithelial-to-mesenchymal transition are
assessing the efﬁcacy of TGF-b inhibitors, connective tissue-
growth factor inhibitors, endothelin-1 antagonists, and bone
morphogenic protein-7 agonists.84 SSAO inhibitors might
become a similar candidate in the future.
The prevention of leukocyte extravasation by SSAOi has
been reported.37 Because white blood cell counts were low-
ered signiﬁcantly by multiple CP treatments, as shown in
Supplementary Figure S2, we consider that the role of neu-
trophils in this model might be less prominent than in other
mouse models of kidney injury. However, the decrease in
F4/80-positive macrophage inﬁltration with SSAOi treatment,
together with the suppression of monocyte chemoattractant
protein-1 and IL-6 mRNA, suggests the contribution of
SSAOi to prevent macrophage from accumulation in this
model. CP-induced renal injury is characterized by activation
of pro-inﬂammatory cytokines. Reportedly, TNF-a has a
crucial role in the activation of this cytokine response.44 The
expressions of TNF-a and IL-6 in the kidney were increased
signiﬁcantly by CP administrations in this model, which were
reduced by SSAOi treatment.
In conclusion, the results of this study demonstrated that
multiple treatments with CP lead to moderate kidney
dysfunction with increased biomarkers and renal ﬁbrosis. In
this model, SSAO/VAP-1 inhibitor treatment conducted for
1 W attenuated biomarker elevation and pathological injury
of AKD to CKD, with suppression of oxidative stress and lipid
accumulation.MATERIALS AND METHODS
Multiple CP administrations model
All animal experiments were approved by The University of Tokyo
institutional review board and were conducted in accordance with the
National Institute of Health (NIH) Guide for the Care and Use
of Laboratory Animals (U.S. Department of Health and Human
Services, Public Health Services, NIH publication no. 86-23,
1985). Seven-to-eight-week-old male C57BL/6 mice (Japan SLC,
Hamamatsu, Japan) and L-FABP Tg mice were kept in glass-shielded382metabolic cages (Metabolica; Sugiyama-Gen Iriki, Tokyo, Japan) with
free access to food and water. The engineering of human L-FABP
chromosomal Tg mice is detailed elsewhere.47,85 This Tg mouse strain
is not forcibly overexpressing.
In preliminary experiments, CP (Nippon Kayaku, Tokyo, Japan,
10 mg/kg body weight) or saline was administered to wild-type mice
by three intra-peritoneal injections. According to the previous three-
times insult model,48 we administered three successive 10 mg/kg
doses, at 1-W intervals. All the recipients died within 4 W. Therefore,
we set the timing of the injections at 0, 1, and 3 W. A lower CP dose
(3 mg/kg and 5 mg/kg; 0, 1, and 3 W) slightly affected the kidney
function and caused dose-dependent mild ﬁbrosis (Supplementary
Figure S1 online). Blood and urine were collected serially at 1 W
intervals. Mice with BUN > 20 mg/dl at 2 W were eligible for the
rest of the protocol. Kidney function in wild-type and L-FABP Tg
mice did not differ signiﬁcantly (Supplementary Figure S3A and B
online). Therefore, we evaluated this protocol in L-FABP Tg mice.
Mice were killed at 4 W after the ﬁrst CP injection, at which time
their kidneys were collected for analyses. To assess the cumulative
CP-induced toxicity for this model, some mice (n ¼ 6) were killed at
3 W after the ﬁrst CP injection (Figure 1e, Supplementary Figure S4
online). Changes in hemoglobin and white blood cell, red blood cell,
and platelet counts of L-FABP Tg mice were assessed (MEK-6450;
Nihon Kohden, Tokyo, Japan). For intervention, L-FABP Tg mice
were orally administered 2 mg/kg per day PXS-4728A (selective
SSAOi) or vehicle in a volume of 10 ml/kg starting 3 W after the ﬁrst
CP administration.38 The study protocol is presented schematically
in Supplementary Figure S4 online.
Measurement of BUN and Cre, urinary biomarkers, and
albumin
BUN was measured using the urease indophenol method (Wako
Pure Chemical Industries, Osaka, Japan) with a 96-well plate reader
(Molecular Devices, Sunnyvale, CA) that determined the sample
absorbance at a wavelength of 570 nm. Cre was measured using
high-performance liquid chromatography as described previ-
ously.21,86 Urinary human L-FABP (CMIC, Tokyo, Japan), mouse
neutrophil gelatinase–associated lipocalin (BioPorto, Gentofte,
Denmark), mouse KIM-1 (R&D Systems, Minneapolis, MN), and
mouse albumin (Exocell, Philadelphia, PA) were measured according
to the manufacturers’ instructions.
Morphologic evaluation of kidneys
For histological examination, the kidneys were resected after
perfusion with phosphate-buffered saline. Formalin-ﬁxed sections
were stained with periodic acid-Schiff stain, MT, and immunohis-
tochemistry. Morphological evaluation of ATN was performed using
established criteria in a blind manner.87,88 Proximal tubule necrosis,
brush-border loss, cast formation, tubule dilatation, and tubular
degeneration were rated on a scale of 0–2 using kidney sections for
each experimental condition. ATN scores are expressed as the sum of
relative severities for each parameter. After deparafﬁnization, the
nonspeciﬁc reaction for horseradish peroxidase was blocked using
3% hydrogen peroxide in methyl alcohol. Antigen retrieval pro-
cedures using microwaves (H2800; Energy Beam Sciences, East
Granby, CT) were performed for all stainings, except F4/80. Protease
K treatment was required for rat antimouse F4/80 macrophage an-
tigen antibody (MCA497R; AbD Serotec, Bio-Rad Laboratories,
Kidlington, UK). Specimens were blocked using the mouse IgG
blocking reagent (Vector Laboratories, Burlingame, CA) for staining
with mouse monoclonal antibodies. Antibodies against primaryKidney International (2016) 89, 374–385
D Katagiri et al.: SSAO/VAP-1 inhibitor for CP-AKD bas i c re sea r chcollagen IV (Abcam plc., Cambridge, UK),89 4-HHE (NOF, Tokyo,
Japan), 8-OHdG (NOF), and F4/80 were applied to sections and
incubated overnight at 4 C. The following procedures for sections
were followed using an ABC system (Vector Laboratories) according
to the manufacturer’s protocol. For the substrate-chromogen reac-
tion, 3,30-diaminobenzidine tetrahydrochloride (Nichirei, Tokyo,
Japan) was used. These sections were counterstained with hema-
toxylin. All these staining procedures were evaluated using Nikon
light microscopy. Collagen I and III were stained with the Picrosirius
Red Stain kit (Polysciences, Warrington, PA) according to the
manufacturers’ protocol. Polarizing microscopy was used for this
staining.90 Images were captured using a microscope and a charge-
coupled device (Nikon, Tokyo, Japan). For Oil Red O staining, 0.3 g
of Oil Red O (Sigma-Aldrich, St Louis, MO) was diluted with 100 ml
of 99% isopropanol and incubated overnight at 60 C. Frozen sec-
tions were ﬁxed in 4% paraformaldehyde and then stained for
15 min at 37 C in 0.18% Oil Red O solution diluted with double-
distilled water.91 Staining for human L-FABP was performed using a
monoclonal antibody (CMIC, Tokyo, Japan), which does not
cross-react with mouse L-FABP, as described previously.85 The MT-,
8-OHdG-, 4-HHE-, collagen type I-, III-, IV-, Oil Red O-, and
L-FABP-positive areas were evaluated using image analysis software
(MCID; Interfocus Imaging, Cambridge, UK) in 10 randomly
selected, non-overlapping ﬁelds at 400 magniﬁcation in each sec-
tion of the renal cortex. To assess the tubular superoxide levels, DHE
histochemistry was performed as described previously.42 DHE is
converted by superoxide to hydroethidium, which binds to DNA.
After ﬁxing with 4% paraformaldehyde, frozen sections cut in 8-mm
pieces were incubated with 200 mmol/l DHE (Molecular Probes,
Waltham, MA) in a light-protected and humidiﬁed chamber for 1 h
at 37 C. Five non-overlapping images per section were analyzed
using confocal ﬂuorescent microscope (LSM 510 Meta NLO Imaging
System; Carl Zeiss, Oberkochen, Germany). The signal was quanti-
ﬁed using image software (ZEN 2009; Carl Zeiss).92
Measurement of SSAO activity
The activities of SSAO in whole-kidney homogenates were assessed
using an assay, protocol of which was reported previously.76,93
Actually, SSAO activity was determined by ﬂuorometry, using
Amplex Red (Invitrogen, Waltham, MA), to measure hydrogen
peroxide production, according to the manufacturer’s instructions.
Brieﬂy, 100 ml kidney homogenates were pre-incubated with 2.0 ml of
dimethyl sulfoxide or the inhibitor mofegiline29 for 30 min at room
temperature. Then 0.5 mM pargyline was added to inhibit any
monoamine oxidase activity. After adding 100 ml reaction buffer
(120 mmol Amplex Red, 1.5 U/ml horseradish peroxidase, 80 mM
benzylamine, in sodium-phosphate buffer), the ﬂuorescence (exci-
tation 565 nm; emission 590 nm) was read over 30 min using a
ﬂuorescence microplate reader (Molecular Devices). Slope (RFU/
min) and SSAO activity were calculated after subtracting the activity
measured by mofegiline.
Measurement of mRNA expressions by quantitative real-time
PCR
At 4Wof the experiment (1 Wafter the third injection of CP or saline;
see Supplementary Figure S3 online), total RNA was extracted from
whole-kidney homogenates using TRIzol (Invitrogen, Waltham, CA).
A Quanti Tect Reverse Transcription Kit (Qiagen, Hilden, Germany)
was used to synthesize cDNA from total RNA. Transcripts encoding
a-SMA, VEGF, TNF-a, and IL-6 were measured using SYBR Green-
based quantitative PCR with Power SYBR Green PCR Master MixKidney International (2016) 89, 374–385(Thermo Fisher Scientiﬁc, South San Francisco, CA) and a sequence
detection system (ViiA 7; Thermo Fisher Scientiﬁc), according to the
manufacturer’s instructions. The sequences of primers were the
following: murine a-SMA (forward: 50-GTCCCAGACATCA
GGGAGT–AA-30: reverse: 50-TCGGATACTTCAGCGTCAGGA-30),
murine VEGF (forward: 50-CCACGTCAGAGAGCAACA–TCA-30:
reverse: 50-TCATTCTCTCTATGTGCTGGCTTT-30), murine TNF-a
(forward: 50-ATC–CGCGACGTGGAACTG-30: reverse: 50-ACCG
CCTGGAGTTCTGGAA-30), and murine IL-6 (forward: 50-TT
CCATCCAGTTGCCTTCTT-30: reverse: 50-ATTTCCACGATTTCC
CAGAG-30). In a separate tube, TGF-b, MCP-1, hL-FABP, and 18 S
ribosomal RNA (18 S rRNA)were ampliﬁedusingTaqManquantitative
PCR. TaqMan probes, primers for TGF-b (assay identiﬁcation number
Mm00441724_m1), MCP-1 (Mm00441242_m1), and hL-FABP
(Hs00155026_m1) were assay on-demand gene expression products
(ThermoFisher Scientiﬁc). The 18 S rRNATaqManprobe (#4319413E)
was also obtained fromThermo Fisher Scientiﬁc. Standard curves were
prepared for each gene and 18 S rRNA in each experiment to normalize
the relative expression of the genes of interest to 18 S rRNA.
Statistical analysis
Data are expressed as mean values  s.e.m. Differences among
experimental groups were assessed using one-way ANOVA with post
hoc analysis, with calculations performed using software (JMP 11.2;
SAS Institute, Cary, NC).DISCLOSURE
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